VEGFR1/2/3, FGFR1/2/3, PDGFR-α, c-Kit

Class

Multi-target antiangiogenic tyrosine kinase inhibitor

Pathway

Inhibits VEGFR2/PDGFRβ/FGFR1 activation and downstream ERK signaling, blocking tumor angiogenesis and proliferation

This mechanism targets a family of receptor tyrosine kinases that sit on cell surfaces and, once activated by their matching growth factors, switch on internal signaling that drives new blood vessel formation (angiogenesis) and cell division. VEGFR1/2/3 are the main receptors for vascular endothelial growth factor and are central to angiogenesis in the cells lining blood vessels. FGFR1/2/3 respond to fibroblast growth factors, PDGFR-α to platelet-derived growth factor, and c-Kit to stem cell factor; together these pathways support vessel maturation, recruitment of supporting cells around vessels, and tumor cell growth. Solid tumors require angiogenesis to obtain oxygen and nutrients once they exceed a small size, and blocking VEGFR signaling alone frequently prompts tumors to upregulate FGF or PDGF signaling as an escape route. A single molecule inhibiting all four receptor families is designed to close these compensatory pathways, producing broader antiangiogenic and antiproliferative activity than a VEGFR-selective agent alone. This multi-target profile is relevant across many solid tumor types where angiogenesis and growth-factor receptor signaling sustain tumor expansion, including cancers that adapt to more narrowly focused therapies.